COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany
-
Published:2022-07-11
Issue:1
Volume:4
Page:
-
ISSN:2524-3489
-
Container-title:Neurological Research and Practice
-
language:en
-
Short-container-title:Neurol. Res. Pract.
Author:
Scherbaum Raphael, Bartig Dirk, Richter Daniel, Kwon Eun Hae, Muhlack Siegfried, Gold Ralf, Krogias Christos, Tönges LarsORCID
Abstract
Abstract
Background
The individualized clinical and public health management of the COVID-19 pandemic have changed over time, including care of people with PD. The objective was to investigate whether in-hospital COVID-19 outcomes and hospital care utilization of people with PD differed between the first two pandemic waves (W) 2020 in Germany.
Methods
We conducted a nationwide cross-sectional study of inpatients with confirmed COVID-19 and PD between March 1 and May 31 (W1), and October 1 and December 31 (W2), 2020 and 2019, using an administrative database. Outcomes were in-hospital mortality, ICU admission rate, change in hospital care utilization, demographical data, PD clinical characteristics, and selected comorbidities. Differences were assessed between waves, PD/non-PD groups, and years.
Results
We identified 2600 PD COVID-19 inpatients in W2 who in total showed higher in-hospital mortality rates and lower ICU admission rates, compared to both W1 (n = 775) and W1/W2 non-PD COVID-19 inpatients (n = 144,355). Compared to W1, W2 inpatients were more long-term care-dependent, older, more of female sex, and had less advanced disease. During both waves, PD inpatients were older, more frequently male and long-term care-dependent, and showed more risk comorbidities than non-PD COVID-19 inpatients. Decreases in hospital care utilization were stronger than average for PD inpatients but relatively weaker during W2. Non-COVID-19 PD inpatients showed poorer in-hospital outcomes in 2020 than in 2019 with better outcomes during W2.
Conclusions
In-hospital COVID-19 outcomes and hospital care utilization of PD patients in Germany differed between the two pandemic waves in 2020 with increased in-hospital mortality for PD COVID-19. Overall hospital care utilization for PD was increased during W2.
Trial registration
No trial registration or ethical approval was required because data were publicly available, anonymized, and complied with the German data protection regulations.
Publisher
Springer Science and Business Media LLC
Subject
Automotive Engineering
Reference71 articles.
1. Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020). Effects of COVID-19 on Parkinson’s disease clinical features: A community-based case-control study. Movement Disorders: Official Journal of the Movement Disorder Society, 35(8), 1287–1292. https://doi.org/10.1002/mds.28170 2. Artusi, C. A., Romagnolo, A., Imbalzano, G., Marchet, A., Zibetti, M., Rizzone, M. G., & Lopiano, L. (2020). Covid-19 in Parkinson’s disease: Report on prevalence and outcome. Parkinsonism and Related Disorders, 80, 7–9. https://doi.org/10.1016/j.parkreldis.2020.09.008 3. Roy, C. M., Bollman, E. B., Carson, L. M., Northrop, A. J., Jackson, E. F., & Moresky, R. T. (2021). Assessing the indirect effects of COVID-19 on healthcare delivery, utilization, and health outcomes: A scoping review. European Journal of Public Health, 31(3), 634–640. https://doi.org/10.1093/eurpub/ckab047 4. Helmich, R. C., & Bloem, B. R. (2020). The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. Journal of Parkinson’s Disease, 10(2), 351–354. https://doi.org/10.3233/JPD-202038 5. Artusi, C. A., Romagnolo, A., Ledda, C., Zibetti, M., Rizzone, M. G., Montanaro, E., Bozzali, M., & Lopiano, L. (2021). Covid-19 and Parkinson’s disease: What do we know so far? Journal of Parkinson’s Disease, 11(2), 445–454. https://doi.org/10.3233/JPD-202463
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|